問卷

TPIDB > Search Result

Search Result

篩選

List

7Cases

2024-07-01 - 2026-12-31

Phase I/II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-02-01 - 2027-12-31

Phase II

Completed
A randomized, blinded, placebo-controlled phase 2 trial evaluating the safety, tolerability, quantitative pharmacology, and efficacy (MAGIC) of DNTH103 in adult patients with generalized myasthenia gravis.
  • Condition/Disease

    ● Evaluate the safety and tolerability of DNTH103 in patients with generalized myasthenia gravis (gMG) up to week 13.

  • Test Drug

    DNTH103 150 mg/mL

Participate Sites
8Sites

Recruiting8Sites

2025-09-15 - 2030-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-05-01 - 2027-06-24

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2024-04-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-12-01 - 2026-09-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-04-01 - 2025-09-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting3Sites

Terminated2Sites